United Therapeutics (NASDAQ:UTHR) CFO Sells $5,771,800.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $577.18, for a total transaction of $5,771,800.00. Following the sale, the chief financial officer owned 18,876 shares of the company’s stock, valued at approximately $10,894,849.68. This represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

James Edgemond also recently made the following trade(s):

• On Monday, April 13th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $574.88, for a total transaction of $5,748,800.00.
• On Thursday, April 9th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.89, for a total transaction of $5,778,900.00.
• On Monday, April 6th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $558.40, for a total transaction of $5,584,000.00.
• On Thursday, April 2nd, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $561.50, for a total transaction of $5,615,000.00.
• On Monday, March 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $593.17, for a total transaction of $5,931,700.00.
• On Thursday, March 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $535.90, for a total transaction of $5,359,000.00.
• On Monday, March 23rd, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00.

United Therapeutics Stock Performance

Shares of UTHR stock traded up $7.87 during trading hours on Friday, reaching $588.38. The company had a trading volume of 662,752 shares, compared to its average volume of 499,787. The business has a fifty day moving average price of $524.67 and a 200-day moving average price of $488.35. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $607.89. The firm has a market cap of $25.79 billion, a PE ratio of 21.09, a price-to-earnings-growth ratio of 1.65 and a beta of 0.75.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. During the same period in the previous year, the business posted $6.19 earnings per share. The business’s revenue for the quarter was up 7.4% on a year-over-year basis. Equities research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Unusual bullish options flow — Traders bought 15,930 UTHR call options on Friday (about a 665% jump versus average call volume), indicating speculative or hedged bullish positioning that can amplify near-term upside or volatility.
• Positive Sentiment: Analyst target increases and constructive coverage — Multiple firms have raised price targets recently (examples cited include Morgan Stanley, Oppenheimer, BofA and RBC) and the consensus remains a “Moderate Buy” with an average target near $601.50, supporting positive investor sentiment. Analyst Coverage & MarketBeat Summary
• Neutral Sentiment: Small CEO sale disclosed — CEO Martine Rothblatt sold 75 shares (March 13) for roughly $40k; the size is immaterial to overall ownership and is unlikely on its own to drive stock direction. InsiderTrades Alert
• Neutral Sentiment: Institutional/hedge fund activity — Several funds adjusted positions (some added, some trimmed); UTHR remains heavily institutionally owned (~94%), which tends to moderate retail-driven swings. MarketBeat: Insider & Institutional Activity
• Negative Sentiment: Material insider selling by CEO — Martine Rothblatt sold 9,500 shares on April 15 (~$5.5M at ~$580.36), a significant reduction in her reported holding per filings; large insider sales can be perceived negatively by investors. SEC Filing: CEO Sale
• Negative Sentiment: Large EVP sale — EVP Paul A. Mahon sold 8,300 shares on April 16 for roughly $4.79M, a meaningful insider disposition that may pressure sentiment if more insider sales follow. SEC Filing: EVP Sale

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of UTHR. Torren Management LLC purchased a new position in shares of United Therapeutics during the 4th quarter worth $26,000. Activest Wealth Management lifted its holdings in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares in the last quarter. WealthCollab LLC lifted its holdings in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. lifted its holdings in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares in the last quarter. Finally, Entrust Financial LLC purchased a new position in United Therapeutics during the fourth quarter valued at approximately $31,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. HC Wainwright lifted their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Wells Fargo & Company raised their price objective on shares of United Therapeutics from $486.00 to $575.00 and gave the stock an “equal weight” rating in a report on Tuesday, March 31st. Morgan Stanley upped their target price on shares of United Therapeutics from $471.00 to $519.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. Royal Bank Of Canada increased their price target on shares of United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Finally, Bank of America lifted their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 31st. Ten research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $601.50.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.